Accelerating Innovation at Leica Biosystems

Recent Financial Highlights Strong performance in first half and into Q3 - - 1H 2021 core revenue growth +31.0% driven by broad-based strength across the portfolio 1H 2021 Adjusted Diluted EPS growth ~100%, $3.4B of FCF was up >70% y/y Q3 tracking in line with expectations Anticipate 2021 core revenue growth of ~20% 2021E: ship ~50M COVID-related Cepheid tests 2021E: ~$2B of COVID-related vaccine & therapeutic revenue at Cytiva & Pall Announced 10 acquisitions for >$10B Closed Aldevron: expands our capabilities into the important field of genomic medicine First bolt-ons for Cytiva (VanRx, Intermountain Life Sciences) and IDT (Swift Biosciences) Strong momentum heading into 2H'21 and 2022 DANAHER

View entire presentation